Projektbeschreibung
Augentropfen gegen autoimmunbedingte schwere Augenerkrankungen
Augenentzündungen (Uveitis) sind eine vielfältige Gruppe autoimmun- oder infektiös bedingter Entzündungskrankheiten, die zur Erblindung führen können. Obwohl die Symptome mit entzündungshemmenden Steroiden behandelbar sind, ist noch keine wirksame Heilung in Sicht. Der Dauereinsatz von Steroiden kann zudem schwere Komplikationen verursachen. So entwickelt das Projekt TRS ein patentiertes biologisch inspiriertes Molekül, das die Autoimmunreaktion und damit den Krankheitsfortschritt unterbricht, statt nur Symptome zu lindern. Entweder in Form von Augentropfen oder als Injektion kann dann je nach spezifischer Krankheit jeder Teil des Auges behandelt werden. Mit den EU-Mitteln werden klinische Studien unterstützt, um letztlich die Markteinführung finanzieren zu können.
Ziel
Ocular inflammatory diseases – affecting hundreds of millions of people worldwide – impose a significant medical and economic burden on society and can lead to blindness. Today, corticosteroids are the most common method used to treat ocular non-infectious inflammation of any kind. Rather than treating the disease itself, however, steroids merely relieve its symptoms, and long-term use can result in devastating consequences.
Our bio-inspired drug candidate is a non-steroid. It approaches inflammatory diseases from within the immune system and was developed to ‘re-engineer’ the immune system. Based on excellent preclinical results, we believe that this approach will have the capability to disrupt the immune mechanism that causes the disease in order to provide patients with a safe and long-lasting therapeutic effect, with the goal of saving them from blindness.
Our platform technology has the potential to effectively treat a broad array of autoimmune and inflammatory diseases and to become a first in class, market approved molecule for local treatment of inflammatory ocular diseases.
Our first target indication is uveitic glaucoma – a devastating orphan disease requiring urgent treatment and carrying high risk of blindness. Selecting an orphan indication as a market penetration strategy will grant us extended market exclusivity, tax reliefs and shorter time to market.
In the project, we will perform a Phase I/IIa clinical trial. We will exploit the trial results to secure financing for further clinical development towards commercialization. The global ocular inflammation treatment market is expected to exceed more than US$ 500 Billion by 2024. As our first target indication has a significant unmet need with no approved treatment, we expect to gain 25% of market shares 5 years post launch, which would correspond to >€700 M in revenue for Tarsius in 2028 for uveitic glaucoma only. Profits will be reinvested to develop our product pipeline and expand our company.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesclinical medicineophthalmologyglaucoma
- medical and health scienceshealth sciencesinflammatory diseases
- medical and health sciencesbasic medicineimmunology
- social sciencessociologygovernancetaxation
Schlüsselbegriffe
Programm/Programme
Thema/Themen
Aufforderung zur Vorschlagseinreichung
Andere Projekte für diesen Aufruf anzeigenUnterauftrag
H2020-SMEInst-2018-2020-2
Finanzierungsplan
SME-2 - SME instrument phase 2Koordinator
3093765 Zichron Yaakov
Israel
Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen).